SANTA ANA, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- TTM Technologies, Inc. (NASDAQ:TTMI) today announced that its Board of Directors authorized a new share repurchase program allowing the Company to repurchase its outstanding common stock with an aggregate market value of up to $100 million from time to time through May 7, 2027. The Company’s previous two-year repurchase program expired on May 3, 2025. “Given the company’s solid cash flow generation and strong balance sheet, we believe repurchasing shares i ...

NASHVILLE, Tenn., May 09, 2025 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties (NYSE: RHP) (the “Company”), today announced that the Board of Directors has authorized, and the Company has declared a second quarter cash dividend of $1.15 per share of common stock, to be paid on July 15, 2025, to stockholders of record as of June 30, 2025. About Ryman Hospitality Properties, Inc. Ryman Hospitality Properties, Inc. (NYSE: RHP) is a leading lodging and hospitality real estate investment trust that specializes ...

Core Insights - illumin Holdings Inc. reported a 17% year-over-year increase in revenue for Q1 2025, reaching $29.1 million, driven primarily by a 148% surge in Exchange service revenue [3][4][6] - The company successfully onboarded 18 new Self-service clients, aligning with its strategy to attract higher-spend clients [3][4] - Despite revenue growth, the company experienced a net loss of $1.9 million, attributed to increased operating costs and a lower net foreign exchange gain [4][6] Financial Performance - Total revenue for Q1 2025 was $29.1 million, up from $24.95 million in Q1 2024 [4][17] - Exchange service revenue increased to $12.0 million, a 148% rise from the previous year, while Managed service revenue decreased to $8.7 million from $11.8 million [4][17] - Self-service revenue was $8.4 million, representing 29% of total revenue, showing slight year-over-year growth [4][17] Operational Highlights - Gross margin for Q1 2025 was 45%, down from 47% in the same period last year, reflecting a shift towards lower-margin services [4][17] - Adjusted EBITDA loss was $0.4 million, compared to a break-even result in Q1 2024, due to higher sales and marketing expenses [4][6] - The company maintained a strong cash position with cash and cash equivalents at $54.0 million as of March 31, 2025 [4][17] Strategic Initiatives - The company is focusing on a customer-centric portfolio platform approach, allowing clients to select their support options [3][4] - Continued investments in the Self-service platform and Exchange service are being balanced with liquidity and cost management efforts [3][4] - The company has initiated a normal course issuer bid (NCIB) to repurchase up to 3,914,167 common shares, representing approximately 10% of its public float [4]

N2OFF to take part in financing a 35MW/140MWh planned Battery Energy Storage System project in Poland Neve Yarak, Israel, May 09, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.(NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech, announced Solterra’s entry into the Polish renewable energy market by participating in the financing of a Battery Energy Storage System (BESS) project in Poland. The project, currently planned at ...

PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision and Ophthalmology (ARVO) showing the potential for zervimesine (CT1812) to protect retinal pigment epithelial (RPE) cells from damage in dry age-related macular degeneration (dry AMD). "Dry AMD is driven by a number of factors that contribute to the death of ...

Core Insights - Spectral Medical Inc. has completed enrollment for its Tigris trial, a Phase III clinical trial evaluating PMX for endotoxic septic shock, with topline results expected in August 2025 [1][2][3] - The company has entered into a promissory note agreement with Vantive for up to US$10 million to support PMX commercialization [1][9] Clinical Development - The Tigris trial has enrolled a total of 157 patients, with 151 evaluable patients and 100 treated with PMX [6] - The data lock for the trial is expected to be completed in approximately 90 days, with topline results anticipated two weeks post-data lock [6] - The company is on track to submit clinical results to the FDA by the end of October 2025 [6] Financial Performance - Revenue for Q1 2025 was $572,000, a decrease of 14% from $668,000 in Q1 2024 [10] - Operating expenses increased significantly to $13,174,000, up 173% from $4,825,000 in the prior year, primarily due to non-cash fair value adjustments [11] - The company reported a loss of $12,605,000 for Q1 2025, compared to a loss of $4,160,000 in Q1 2024 [13] Balance Sheet and Financing - As of March 31, 2025, the company had cash of $1,670,000, down from $2,988,000 at the end of 2024 [14] - The promissory note with Vantive includes a four-year maturity and a payment-in-kind interest rate of 9% [15] Commercialization Activities - The company is collaborating with Vantive on post-approval marketing plans for PMX commercialization [15] - Vantive intends to submit a 510(k) application for its PrisMax System, which is expected to be the primary device used for PMX treatments upon commercial launch [15] Regulatory and Clinical Study Insights - The EDEN study, completed in Q4 2023, showed that patients with endotoxic septic shock had a significantly higher mortality rate of 60% compared to 14.1% for other septic shock patients [6] - The results from the EDEN study will inform discussions with the FDA regarding PMX labeling and the addressable population in the U.S. [6]

Core Viewpoint - PyroGenesis Inc. is set to host a conference call on May 14, 2025, to discuss its financial results for Q1 2025 and provide updates on company progress and developments [1]. Company Overview - PyroGenesis is a high-tech company specializing in advanced all-electric plasma processes and sustainable solutions aimed at supporting heavy industries in energy transition, emission reduction, commodity security, and waste remediation [1][3]. - The company has developed proprietary and patented plasma technologies that are being adopted by major industry players in four key markets: iron ore pelletization, aluminum, waste management, and additive manufacturing [3]. - PyroGenesis operates from its Montreal office and has manufacturing facilities of 3,800 m² and 2,940 m², maintaining a competitive edge through continuous technology development and commercialization [3]. - The company is ISO 9001:2015 and AS9100D certified, having been ISO certified since 1997 [3]. - PyroGenesis' shares are publicly traded on the TSX (TSX: PYR), OTCQX (OTCQX: PYRGF), and Frankfurt Stock Exchange (FRA: 8PY1) [3].

HOUSTON, May 09, 2025 (GLOBE NEWSWIRE) -- Plains All American Pipeline, L.P. (Nasdaq: PAA) and Plains GP Holdings (Nasdaq: PAGP) today reported first-quarter 2025 results and provided the following highlights: First-Quarter Results Reported net income attributable to PAA of $443 million and net cash provided by operating activities of $639 millionDelivered Adjusted EBITDA attributable to PAA of $754 millionExited the quarter with 3.3x leverage ratio, toward the low end of our target range of 3.25x - 3.75x ( ...

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition at the market opening of 320,000 shares in Alvotech at ISK 1,255 per share, by Robert Wessman, Chairman and CEO. ...

Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025 SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced publication of results from the ...